Welcome to our dedicated page for Champions Oncolo news (Ticker: CSBR), a resource for investors and traders seeking the latest updates and insights on Champions Oncolo stock.
Champions Oncology, Inc. reports developments as a translational oncology research organization serving biopharma drug discovery and development. The company’s updates center on preclinical and clinical research services, patient-derived xenograft (PDX) and primary hematological malignancy models, proprietary in vivo and ex vivo platforms, bioanalytical capabilities, and data services that connect tumor models with molecular and clinical datasets.
Recurring news themes include quarterly operating results, study service revenue, bookings and backlog conversion, data platform investment, research presentations at oncology meetings, and governance changes. Company research updates describe model-based studies of therapeutic response, resistance, biomarkers, and tumor biology across oncology development programs.
Champions Oncology, Inc. (CSBR) will report its second quarter financial results for the period ended October 31, 2022, on December 13, 2022, after market close. The company specializes in drug discovery through AI-driven pharmaco-pheno-multiomic integration and offers innovative research services to biopharma organizations. A conference call discussing the results will take place at 4:30 PM EST on the same day, with dial-in options available for both domestic and international participants. A replay will be accessible within 72 hours.
Champions Oncology (NASDAQ:CSBR) reported record revenue of $13.7 million for Q1 fiscal 2023, marking a 22.1% year-over-year increase. The adjusted EBITDA was $450,000, reflecting growth in its service offerings. Total operating expenses rose to $14 million, leading to a loss from operations of $284,000. Despite rising costs, the company ended the quarter with a strong cash position of $8.1 million and no debt. The report highlights significant bookings and advancements in drug discovery partnerships.
Champions Oncology (NASDAQ:CSBR) will announce its first quarter financial results for the period ending July 31, 2022, on September 8, 2022, post-market close. A conference call is scheduled for the same day at 4:30 PM EDT to discuss the results. Investors can join the call by dialing 888-506-0062 (Domestic) or 973-528-0011 (International). A replay will be available afterwards, along with access on the company's website within 72 hours. Champions Oncology focuses on transforming drug discovery through innovative approaches.
Champions Oncology (NASDAQ:CSBR) reported a record annual revenue of $49.1 million for fiscal year 2022, a 20% increase year-over-year. Fourth-quarter revenue rose 22% to $12.9 million. The company achieved a gross margin of 52% and an adjusted EBITDA of $3.1 million for the year. Operating expenses increased 19%, driven by higher costs in research and development and general administrative expenses. Despite reporting a loss from operations of $311,000 in Q4, Champions ended the year with a strong cash position of $9.0 million and no debt.
Champions Oncology (CSBR) will announce its fourth quarter financial results for the period ending April 30, 2022, on July 21, 2022, after market close. A conference call is scheduled for 4:30 P.M. EDT to discuss these results, with participation details provided for both domestic and international callers. Champions Oncology specializes in AI-driven drug discovery and offers various R&D services to biopharma organizations, enhancing research efficiency and effectiveness.
Champions Oncology (NASDAQ:CSBR) and Cyclica have announced a new therapeutic development partnership aimed at creating a small molecule drug discovery program. This initiative will focus on therapeutic targets linked to various solid tumors, including non-small cell lung cancer and head and neck cancer. Champions will lead the program, co-owning it with Cyclica, and is expected to make milestone and royalty payments upon achieving specific goals. Both companies emphasize the potential for improving patient outcomes through innovative drug discovery.
Champions Oncology, Inc. (NASDAQ:CSBR) announced its Lumin Bioinformatics Platform has been selected as a finalist for the 'Best in Show' Competition at the Bio-IT World Conference & Expo. The demonstration will take place on May 4th. Lumin is a powerful tool that provides access to over 2 billion data points from more than 12,000 cancer patients, enabling advanced analytics and integration of user data. CEO Ronnie Morris emphasized the platform's evolving capabilities and its role in transforming cancer research and biomarker discovery.
Champions Oncology, Inc. (Nasdaq:CSBR) reported a record quarterly revenue of $13.2 million for Q3 of fiscal 2022, reflecting a 22% year-over-year increase. Despite increased operating costs of $12.4 million, the company achieved an adjusted EBITDA of $1.5 million. Gross margin improved to 51.4% over the nine months ended January 31, 2022, while net income from operations stood at $830,000. With strong cash reserves of $8.7 million and no debt, Champions continues to invest in strategic partnerships and therapeutic discovery.
Champions Oncology (CSBR) will release its third quarter financial results on March 15, 2022, after market close. The company, known for its AI-driven approach in drug discovery, will hold a conference call at 4:30 P.M. EDT to discuss these results. Interested parties can join the call using specific dial-in numbers. Champions Oncology is focused on cancer therapeutics and R&D services, leveraging innovative technologies to transform drug development.
Champions Oncology (NASDAQ:CSBR) has announced a strategic partnership with GigaMune to co-develop advanced T cell therapies and cancer diagnostics. The collaboration aims to utilize Champions' Autologous Tumor Infiltrating Lymphocyte (TIL) platform alongside GigaMune's T Cell Receptor (TCR) Discovery technology to identify novel TCR sequences. This effort seeks to create unique libraries of TCRs for clinical applications, focusing on solid tumor indications. Champions will retain rights for selected TCRs while jointly owning the remaining libraries for further commercialization.